P. falciparum Malaria: Developing a Synthetic Subunit Candidate Vaccine

Malaria is one of the most serious infectious diseases of humans, infecting 5–10% of the world’s population, with 300–600 million clinical cases and more than 2 million deaths annually. Moreover, malaria is a major social and economic burden in endemic areas. In recent years, malaria has spread at an alarming rate owing to the increasing resistance of the parasite to drugs, and the resistance of mosquitoes to insecticides. Therefore, new approaches to combat malaria are urgently needed, and a vaccine is predicted to have the greatest impact in addition to being the most cost-effective control measure.

Vaccine Development

One approach is to design a subunit vaccine that incorporates several malaria protein antigens for which there is evidence of protective immunity from epidemiological data or experimental animal challenge models. Development of such subunit vaccines is critically dependent on the availability of an antigen delivery system to drive suitable protein antigen-specific immune responses in humans. Vaccine formulations have to be highly effective, human-compatible and safe. Production of synthetic or recombinant proteins that stably mimic the native structure of the corresponding malaria antigens to induce effective humoral immune responses is a further major challenge.

Our research

We are addressing both problems by developing synthetic peptide structures that induce cross-reactive antibodies against the parent malaria proteins and by coupling them to the surface of immunopotentiating reconstituted influenza virosomes (IRIVs). In addition we are evaluating the use of so fare uncharacterized predicted proteins of Plasmodium falciparum as potential new candidate vaccine antigens.


Ahn J, Sinka M, Irish S, Zohdy S. Modeling marine cargo traffic to identify countries in Africa with greatest risk of invasion by Anopheles stephensi. Sci Rep. 2023;13:876. DOI: 10.1038/s41598-023-27439-0

Alahmad B et al. Associations between extreme temperatures and cardiovascular cause-specific mortality: results from 27 countries. Circulation. 2023;147(1):35-46. DOI: 10.1161/CIRCULATIONAHA.122.061832

Anvari M.S, Belus J.M, Regenauer K.S, Myers B, Joska J, Magidson J.F. The combination of HIV and alcohol use internalized stigmas are associated with greater symptoms of depression in a South African sample living with HIV. Stigma Health. 2023;7(3):370-373. DOI: 10.1037/sah0000394

Banatvala N, Wyss K, Akweongo P, Kuwawenaruwa A, Grodwin V. Universal health coverage and NCD prevention and control. In: Banatvala N,Bovet P, eds. Noncommunicable diseases: a compendium, 277-284. London, New York: Routledge, 2023. DOI: 10.4324/9781003306689

Bulthuis S et al. How to scale-up: a comparative case study of scaling up a district health management strengthening intervention in Ghana, Malawi and Uganda. BMC Health Serv Res. 2023;23:35. DOI: 10.1186/s12913-023-09034-1

Burrows H et al. Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness. Vaccine. 2023(in press). DOI: 10.1016/j.vaccine.2022.12.032

Capone D et al. Urban onsite sanitation upgrades and synanthropic flies in Maputo, Mozambique: effects on enteric pathogen infection risks. Environ Sci Technol. 2023(in press). DOI: 10.1021/acs.est.2c06864

Coulibaly J.T et al. High sensitivity of mobile phone microscopy screening for Schistosoma haematobium in Azaguié, Côte d'Ivoire. Am J Trop Med Hyg. 2023;108(1):41-43. DOI: 10.4269/ajtmh.22-0527

Crellen T et al. Diagnosis of helminths depends on worm fecundity and the distribution of parasites within hosts. Proc Biol Sci. 2023;290(1991):20222204. DOI: 10.1098/rspb.2022.2204

Daubenberger C. Genetically modified malaria parasites as vaccine candidates. Trends Mol Med. 2023;29(1):1-3. DOI: 10.1016/j.molmed.2022.11.005